Seres Therapeutics Market Sentiment

Seres Therapeutics Inc

MCRBNASDAQ

Trade with Public

$1.98

-0.11-5.26%

마지막 업데이트: Oct 26, 5:20 PM

개요 뉴스 실적 전망 이벤트 목표가 재무심리지분 현황 비교 옵션 주식 보고서

Seres Therapeutics Market Sentiment - Benzinga

Seres Therapeutics Market Sentiment

Market sentiment signals for Seres Therapeutics (MCRB): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 4.0% short float

Options Flow— 1.00 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

6 analysts

Options Flow (P/C)

1.00

Balanced — Neutral

1 calls · 1 puts

Avg Consensus PT

$14

+594.0%

Highest Price Target

$22

+1010.4%

Canaccord Genuity

Lowest Price Target

+202.8%

Chardan Capital

Short Interest

4.0%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Jun 23, 2026	HC Wainwright & Co.	Matthew Keller—	+505.7%	$12	Initiate	Buy
Mar 13, 2026	Canaccord Genuity	John Newman—	+1010.4%	$22 → $22	Maintained	Buy
Sep 24, 2025	Canaccord Genuity	John Newman—	+1010.4%	$14 → $22	Maintained	Buy
May 8, 2025	Chardan Capital	Keay Nakae—	+202.8%	$1 → $6	Downgrade	Buy→Neutral
Mar 20, 2025	Chardan Capital	Keay Nakae—	+1161.9%	$25 → $25	Maintained	Buy
Mar 14, 2025	Goldman Sachs	Chris Shibutani—	+657.1%	$20 → $15	Maintained	Sell
Nov 14, 2024	Canaccord Genuity	John Newman—	+9994.9%	$200 → $200	Maintained	Buy
Nov 13, 2024	Chardan Capital	Keay Nakae—	+1161.9%	$25 → $25	Maintained	Buy
Oct 24, 2024	JP Morgan	Tessa Romero—	—	—	Downgrade	Neutral→Underweight
Sep 13, 2024	Canaccord Genuity	John Newman—	+9994.9%	$200 → $200	Maintained	Buy
Aug 14, 2024	Canaccord Genuity	John Newman—	+9994.9%	$200 → $200	Maintained	Buy
Aug 14, 2024	Chardan Capital	Keay Nakae—	+1161.9%	$25 → $25	Maintained	Buy
Jun 7, 2024	Oppenheimer	Jeff Jones—	—	—	Downgrade	Outperform→Perform
Jun 7, 2024	Canaccord Genuity	John Newman—	+9994.9%	$300 → $200	Maintained	Buy
May 9, 2024	Oppenheimer	Jeff Jones—	+3938.0%	$100 → $80	Maintained	Outperform
May 8, 2024	Chardan Capital	Keay Nakae—	+5956.9%	$160 → $120	Maintained	Buy
Mar 6, 2024	Oppenheimer	Jeff Jones—	+4947.4%	$180 → $100	Maintained	Outperform
Mar 6, 2024	Chardan Capital	Keay Nakae—	+7975.9%	$200 → $160	Maintained	Buy
Jan 16, 2024	Oppenheimer	Jeff Jones—	+8985.4%	$200 → $180	Maintained	Outperform
Nov 3, 2023	Goldman Sachs	Chris Shibutani—	+1161.9%	$80 → $25	Maintained	Sell